Washington University in St. Louis

<table class="infobox infobox-institution">
<tr><th class="infobox-header" colspan="2">Washington University in St. Louis</th></tr>
<tr><td class="infobox-image" colspan="2"><em>WashU Logo</em></td></tr>
<tr><td class="label">Location</td><td>St. Louis, Missouri, USA</td></tr>
<tr><td class="label">Type</td><td>Private Research University</td></tr>
<tr><td class="label">Founded</td><td>1853</td></tr>
<tr><td class="label">Website</td><td><a href="https://wustl.edu/" target="_blank">wustl.edu</a></td></tr>
<tr><td class="label">Focus Areas</td><td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), Dementia, Neuroimaging, Genetics</td></tr>
<tr><td class="label">Medical School</td><td>[Washington University School of Medicine](/institutions/washu-school-of-medicine)</td></tr>
</table>

Washington University in St. Louis

Introduction

Washington University In St. Louis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

<table class="infobox infobox-institution">
<tr><th class="infobox-header" colspan="2">Washington University in St. Louis</th></tr>
<tr><td class="infobox-image" colspan="2"><em>WashU Logo</em></td></tr>
<tr><td class="label">Location</td><td>St. Louis, Missouri, USA</td></tr>
<tr><td class="label">Type</td><td>Private Research University</td></tr>
<tr><td class="label">Founded</td><td>1853</td></tr>
<tr><td class="label">Website</td><td><a href="https://wustl.edu/" target="_blank">wustl.edu</a></td></tr>
<tr><td class="label">Focus Areas</td><td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), Dementia, Neuroimaging, Genetics</td></tr>
<tr><td class="label">Medical School</td><td>[Washington University School of Medicine](/institutions/washu-school-of-medicine)</td></tr>
</table>

Washington University in St. Louis

Introduction

Washington University In St. Louis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Washington University in St. Louis (WashU) is one of the world's leading private research universities, founded in 1853. Its School of Medicine is consistently ranked among the top in the nation for neuroscience and neurodegeneration research. The university's Knight Alzheimer's Disease Research Center (ADRC) is one of the original NIH-funded ADRCs and has been instrumental in defining the preclinical and prodromal stages of Alzheimer's disease["@knight"].

WashU's neuroscience community benefits from close integration between the [School of Medicine](/entities/school-of-medicine), the [Division of Biological Sciences](/entities/division-of-biological-sciences), and the [School of Engineering](/entities/chool-of-engineering), enabling multidisciplinary approaches to neurodegeneration.

Neurodegeneration Research Programs

Knight Alzheimer's Disease Research Center

The Knight ADRC, directed by Dr. John Morris, has defined the preclinical Alzheimer's disease cascade and developed biomarker criteria now used worldwide. The center contributes to the [Alzheimer's](/diseases/alzheimers) Clinical Trials Consortium and has pioneered cerebrospinal fluid and PET biomarker discovery[@morris2023].

Hope Center for Neurological Disorders

The Hope Center focuses on understanding the basic biology of neurological disorders, including Alzheimer's, Parkinson's, ALS, and multiple sclerosis. Research spans from molecular mechanisms to translational therapeutics[@hope].

Dominantly Inherited Alzheimer Network (DIAN)

WashU leads the international [DIAN](/entities/dian-study) observational study and clinical trials for individuals with autosomal dominant Alzheimer's disease mutations, providing unique insights into disease pathogenesis decades before symptom onset.

Notable Researchers

• Dr. John Morris — Director, Knight ADRC; Alzheimer's biomarkers
• Dr. Randall Bateman — DIAN director; amyloid and [tau](/proteins/tau) kinetics
• Dr. David Holtzman — [Tau](/proteins/tau) biology and immunotherapy
• Dr. Celeste Karch — Genetic basis of Alzheimer's and ALS
• Dr. Carlos Cruchaga — Genomics and bioinformatics of neurodegeneration

Disease Focus

| Disease | Research Intensity |
|---------|-------------------|
| Alzheimer's Disease | Very High |
| Parkinson's Disease | High |
| ALS | Moderate |
| Frontotemporal Dementia | Moderate |
| Huntington's Disease | Low |

Training Programs

WashU offers extensive training through the [Neuroscience Program](/entities/neuroscience-program), the [MD/PhD Program](/entities/md-phd-program), and the [Postdoctoral Training Program](/entities/postdoctoral-fellowship) in neurodegeneration.

Knight Alzheimer's Disease Research Center

Overview and History

The Knight ADRC, established in 1985 as one of the original NIH-funded Alzheimer's Disease Research Centers, has been a pioneer in Alzheimer's disease research. Directed by Dr. John Morris since its inception, the center has made seminal contributions to understanding the preclinical and prodromal stages of AD[@morris2023]. The Knight ADRC has been instrumental in developing the biomarker framework that now defines the field's research framework, particularly through the influential NIA-AA research framework[@jack2018].

Research Themes

Biomarker Discovery and Validation

The Knight ADRC has led the development and validation of key AD biomarkers:

• CSF Biomarkers: Aβ42, tau, p-tau measurements
• PET Imaging: Amyloid PET using [11C]PIB and [18F]florbetapir[@mintun2006][@rowe2007]
• Neurodegeneration Markers: NFL, neurogranin

Preclinical AD Research

The center defined the concept of preclinical AD:

• Biomarker changes precede clinical symptoms by 20+ years
• Amyloid accumulation begins in midlife
• Tau pathology spreads in a predictable pattern

DIAN: Dominantly Inherited Alzheimer Network

Overview

The Dominantly Inherited Alzheimer Network (DIAN)[@bateman2022] is an international observational study and clinical trials platform led by Washington University. DIAN studies individuals with autosomal dominant AD mutations (APP, PSEN1, PSEN2) who have a predictable age of onset.

Key Findings

• Biomarker changes occur 20+ years before symptoms
• Amyloid plaque formation precedes cognitive decline
• Treatment responses can be assessed in preclinical stages

DIAN Clinical Trials

• Anti-amyloid antibodies in preclinical participants
• Adaptive trial design for rare populations
• Collaboration with pharmaceutical partners

Hope Center for Neurological Disorders

Mission and Focus

The Hope Center for Neurological Disorders[@hope] brings together basic and clinical researchers to understand neurological disorders including:

• Alzheimer's disease
• [Parkinson's disease](/diseases/parkinsons-disease) ALS
• Multiple sclerosis
• Stroke

Research Programs

Tau Biology Program

Led by Dr. David Holtzman[@holtzman2021], this program focuses on:

• Tau pathogenesis and spread
• Tau immunotherapy approaches
• Tau PET imaging development

Neurodegeneration Genetics Program

Led by Dr. Celeste Karch[@karch2018] and Dr. Carlos Cruchaga[@cruchaga2020]:

• Alzheimer's disease genetics
• ALS genetics
• Bioinformatics and genomics

Research Programs and Centers

Center for Neurodegeneration and Repair (CNR)

Interdisciplinary center integrating:

• Basic neuroscience research
• Clinical trials
• Drug discovery

Neuroimaging Laboratory

Advanced neuroimaging capabilities:

• PET/SPECT
• MRI (3T, 7T)
• MEG/EEG

Biomarker Core

Comprehensive biomarker services:

• CSF analysis
• Blood-based biomarkers
• Neuropathology

Notable Faculty and Their Contributions

Dr. John Morris

Director, Knight ADRC; Pioneer in preclinical AD biomarkers:

• Developed cognitive composites for preclinical AD
• Established biomarker thresholds for amyloid positivity
• Led multicenter validation studies

Dr. Randall Bateman

Director, DIAN; Expert in amyloid and tau kinetics:

• Pioneered in vivo measurements of Aβ production/clearance
• Developed stable isotope labeling kinetics (SILK) method
• Led DIAN clinical trials

Dr. David Holtzman

Tau biology and immunotherapy:

• Discovered role of apoE in Aβ metabolism
• Developed anti-tau antibodies
• Characterized tau release mechanisms

Dr. Celeste Karch

Genetic architecture of AD and ALS:

• Identified novel AD risk genes
• ALS genetics research
• Functional genomics

Dr. Carlos Cruchaga

Genomics and bioinformatics:

• Large-scale GWAS and sequencing
• Multi-omics integration
• Biomarker genetics

Clinical Programs

Memory and Aging Program

Comprehensive clinical care and research:

• Memory assessment and diagnosis
• Clinical trials enrollment
• Caregiver support

Lewy Body Dementia Program

Focused on DLB and AD overlap[@poston2013]:

• Clinical characterization
• Biomarker studies
• Treatment trials

Training and Education

Neuroscience Program

WashU offers extensive training:

• PhD in Neuroscience
• MD/PhD programs
• Postdoctoral training

Clinical Research Training

• Clinical trials methodology
• Biomarker science
• Neuroimaging techniques

Research Infrastructure

Data Resources

• Knight ADRC clinical data repository
• DIAN database
• Neuroimaging archive

Sample Resources

• Brain tissue bank
• CSF repository
• DNA bank

Key Publications

| Year | Finding | Impact |
|------|---------|--------|
| 2006 | First amyloid PET in humans[@mintun2006] | Established PET as AD biomarker |
| 2010 | DIAN study design[@masel2010] | Enabled preclinical AD trials |
| 2018 | NIA-AA Framework[@jack2018] | Global research standard |
| 2020 | CSF biomarkers review[@schindler2019] | Clinical implementation guide |
| 2022 | DIAN biomarker findings[@bateman2022] | Preclinical AD pathophysiology |
| 2023 | Preclinical AD update[@morris2023] | Current best practices |

Funding and Partnerships

NIH Funding

• NIA (Alzheimer's Disease Research Centers Program)
• NINDS (Morris K. Udall Centers)
• NIAAA

Industry Partnerships

• Pharmaceutical company collaborations
• Clinical trial agreements
• Diagnostic development

Future Directions

Short-Term Goals (2024-2026)

Expand tau PET validation studies

Blood biomarker implementation

Preventive trials in preclinical AD

Long-Term Goals (2026-2030)

Achieve primary prevention of AD

Develop personalized medicine approaches

Integrate multi-omics into clinical care

Related Centers and Institutions

NIH-Funded ADRC Network

• [Banner Alzheimer's Institute](/institutions/banner-alzheimers-institute)
• [Massachusetts General Hospital](/institutions/massachusetts-general-hospital)
• [University of Pennsylvania](/institutions/university-pennsylvania)

Related Research Programs

• [AMP-AD](/institutions/amp-ad)
• [DIAN](/entities/dian-study)
• [Knight ADRC](/institutions/knight-adrc)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [Tau Protein](/proteins/tau)
• [Amyloid Beta](/proteins/amyloid-beta)
• [Harvard University](/institutions/harvard-university)
• [Columbia University](/institutions/columbia-university)
• [UCSF](/institutions/uc-san-francisco)

External Links

• [Washington University in St. Louis](https://wustl.edu/)
• [Washington University School of Medicine](https://medicine.wustl.edu/)
• [Knight Alzheimer's Disease Research Center](https://knightadrc.wustl.edu/)
• [Hope Center for Neurological Disorders](https://hopecenter.wustl.edu/)
• [DIAN Study](https://dian.wustl.edu/)

References

[Knight Alzheimer's Disease Research Center](https://knightadrc.wustl.edu/)

[Morris JC et al, Preclinical AD: Update on biomarkers and prevention (2023)](https://doi.org/10.1038/s41582-023-00785-5)

[Hope Center for Neurological Disorders](https://hopecenter.wustl.edu/)

[Bateman RJ et al, Dominantly Inherited Alzheimer Network (2022)](https://doi.org/10.1038/s41591-022-01978-9)

[Holtzman DM et al, Tau in Alzheimer disease (2021)](https://doi.org/10.1038/s41582-021-00542-4)

[Karch CM et al, Genetic architecture of Alzheimer's disease (2018)](https://doi.org/10.1038/s41380-018-0032-6)

[Cruchaga C et al, Genomic insights into Alzheimer disease (2020)](https://doi.org/10.1038/s41582-020-0372-8)

[Mittel HS et al, Amyloid PET in Alzheimer's disease (2023)](https://doi.org/10.1038/s41582-023-00698-7)

[Jack CR Jr et al, NIA-AA Research Framework (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)

[Schindler SE et al, CSF biomarkers in Alzheimer disease (2019)](https://doi.org/10.1038/s41582-019-0221-1)

[Fagan AM et al, CSF biomarkers in preclinical AD (2020)](https://doi.org/10.1002/ana.25832)

[Mintun MA et al, [11C]PIB in young adults (2006)](https://pubmed.ncbi.nlm.nih.gov/16741284/)

[Rowe CC et al, Amyloid imaging with PET (2007)](https://pubmed.ncbi.nlm.nih.gov/17573678/)

[PMLi et al, DIAN: Autosomal dominant AD (2021)](https://doi.org/10.1038/s41591-021-01502-7)

[Blennow K et al, Biomarkers for AD (2021)](https://pubmed.ncbi.nlm.nih.gov/34019786/)

[Jansen WJ et al, Prevalence estimates in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35171240/)

[Sperling RA et al, Amyloid imaging in preclinical AD (2014)](https://pubmed.ncbi.nlm.nih.gov/24362760/)

[Poston KL et al, DLB and AD overlap (2013)](https://pubmed.ncbi.nlm.nih.gov/23640382/)

[Masel AM et al, DIAN study design (2010)](https://pubmed.ncbi.nlm.nih.gov/20415578/)